+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

COVID-19 (Coronavirus) Global Market Conditions and Competitors: Cell Therapies, Diagnostics, Treatments, Trials, & Vaccines

  • ID: 5006293
  • Report
  • July 2020
  • Region: Global
  • 269 Pages
  • BioInformant
UP TO OFF
until Jul 31st 2020
1 of 4

FEATURED COMPANIES

  • AlloVir
  • Bonus BioGroup, Ltd.
  • CytoDyn
  • Johnson & Johnson
  • Organicell
  • Sanofi
  • MORE

COVID-19 is the largest pandemic in modern history, with more than ten million confirmed cases and a half million deaths in under six months.

While there is not yet an approved treatment for COVID-19, the scientific, medical, and regulatory agencies are making heroic efforts to bring out new medicines. Numerous COVID-19 product categories have emerged, including vaccines, antibodies, antivirals, repurposed drugs, RNA-based drugs, and cell-based therapies, as well as other approaches, such as enzymes, peptides, and glycoproteins.

This report explores each of these product development categories in detail, presenting the products under development and timelines for them to come to market. Special attention is given to the critical role of cell-based therapies in the management of the global pandemic.

COVID-19 Market Dynamics

Thousands of scientific articles have been published electronically or in print since the outbreak of COVID-19 began in late 2019. Patent activity around COVID-19 is surging, with many companies securing intellectual property (IP) related to the development of COVID-19 therapeutics. To a lesser degree, companies are securing IP around vaccines, diagnostic agents, and methods.

This report reveals rates of COVID-19 scientific publications and presents a global breakdown of COVID-19 patent activity that includes patent type, sponsoring organization, and method of action.

New diagnostic tests for COVID-19 are emerging as an essential tool to track the spread of the disease, as the World Health Organization (WHO) is urging health agencies worldwide to make testing for the virus a top priority. Thus far, the FDA granted Emergency Use Authorization (EUA) for 58 viral RNA-based tests, ten antibody-based tests, one antigen-based test, and one at-home collection kit.

COVID-19 Treatments & Technologies

To accelerate the development of therapies against COVID-19, the repurposing of existing drugs is being explored by numerous market competitors. For example, Barcitinib is being explored because of its anti-inflammatory effect and possible ability to reduce viral entry. A specific dose of the anti-HIV combination, Lopinavir-Nitonavir, is now in clinical trials with Arbidol or Ribavirin. Remdesivir, developed by Gilead Sciences, was earlier tested in patients with Ebola virus and has shown promise in animal models for MERS and SARS. Remdesivir has reached Phase III in the U.S. and China.

Favipiravir, a purine nucleoside leading to inaccurate viral RNA synthesis, was previously developed by Toyama Chemical of Japan and has now been approved for a clinical trial as a drug for the treatment of COVID-19. Chloroquine has shown itself to be effective in treating COVID-19 in China.

Dozens of companies are rushing vaccine development and proceeding toward clinical trials. As select examples, the U.S. NIH initiated a Phase I trial in Seattle evaluating an investigational vaccine (mRNA-1273) created by NIAID scientists and their collaborators at Moderna, Inc. Sanofi and Regeneron launched a Phase II/II trial in New York evaluating the IL-6 targeted Kevzara. Inovio Pharmaceuticals is advancing its vaccine into human trials within the U.S. and intends to produce one million doses of it by the end of the year.

Cell Therapies Against COVID-19

Globally, the healthcare industry is using every weapon in its armory to suppress the threat from the virus, including the use of living therapies such as natural killer (NK) cells, T-cells, stem cells, and exosomes. While many novel approaches are being investigated, stem cells - mesenchymal stem cells (MSCs) in particular - are showing intriguing potential for the treatment of COVID-19.

MSCs are receiving attention because past studies have found the secretions from MSCs to be effective at treating inflammation and cytokine storms. From early-stage studies, it appears that MSC may exert beneficial effects, potentially by improving the lung microenvironment, inhibiting immune system over-activation, promoting tissue repair, protecting lung alveoli epithelial cells, preventing pulmonary fibrosis, or improving lung function.

As leading examples, Athersys, Inc. has reported positive outcomes in other studies using MSCs for treating respiratory disease, and Mesoblast's Remestemcel-L has proved to be effective in treating advanced respiratory distress. Athersys and Mesoblast are enrolling for 300 and 400 patient trials, respectively - two of the largest stem cell trials to date against COVID-19. In total, at least 26 companies are exploring cell therapy products against COVID-19 and its complications.

In recent months, there has been a flurry of activity within the clinical trial sector. When all trial types are considered, there are over 400 studies exploring approaches to diagnosing, treating, or preventing COVID-19. ClinicalTrials.gov has also reported at least 15 trials leveraging stem cells against COVID-19.

COVID-19 Market Trends

The aim of this report is to gather existing research on COVID-19, reveal key insights, and position the reader to identify emerging market opportunities related to the Coronavirus pandemic.

It reveals every known diagnostic, treatment, and vaccine in development worldwide, emphasizing the critical role of cell therapies in the management of the pandemic.

It provides comprehensive coverage of the outbreak, highlights global competitors involved in the fight against COVID-19, and presents product development pipelines, diagnostic testing approaches, vaccine development programs, regulatory approvals, and importantly, trend rate data for COVID-19 scientific publications, patents, and clinical trials on a worldwide basis.

The report includes:

  • Every known diagnostic, treatment and vaccine in development worldwide
  • Leading market competitors advancing solutions against COVID-19 and their commercial strategies
  • Trend rate data for COVID-19 scientific publications, patents, and grants
  • Intellectual property analysis for COVID-19 related IP
  • Regulatory approvals for COVID-19 related technologies
  • Rates, types and sponsors of COVID-19 clinical trials worldwide
  • Company and product descriptions for all living therapies being targeted against COVID-19 worldwide, including stem cells, NK cells, T cells, exosomes and more
  • All clinical trials worldwide involving stem cell therapeutics, both active and withdrawn
  • Funding sources for COVID-related technologies and the companies receiving support

With the rapidly developing nature of this global pandemic, you don't have the time to do the research. Claim this global strategic report to become immediately informed, without sacrificing hours of unnecessary research or being at risk of missing critical market opportunities.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AlloVir
  • Bonus BioGroup, Ltd.
  • CytoDyn
  • Johnson & Johnson
  • Organicell
  • Sanofi
  • MORE

1. REPORT OVERVIEW
1.1 Statement of the Report
1.2 Executive Summary
1.3 Introduction

2. CORONAVIRUS: STRUCTURE, INFECTION, REPLICATION, SYMPTOMS
2.1 Start of the Outbreak
2.1.1 Structure of COVID-19
2.1.2 Structure of COVID-19’s Spike Protein and Enzymes
2.1.3 The Details of COVID-19’s RNA-dependent RNA polymerase (RdRp)
2.1.4 Crystal Structure of COVID-19 Virus’s Protease Enzyme
2.1.5 Structure of COVID-19 virus’s Spike Protein
2.1.6 The Binding of a Patients Antibody with COVID-19 Virus’s Spike Protein
2.1.7 Potential Binding Sites of Human Protein Complex (CUL2ZYG11B)
2.1.8 The Binding of Coronavirus to Target Protein on Human Cell
2.1.9 The Cause of COVID-19 Virus’s Rapid Spread
2.2 The Symptoms of COVID-19
2.3 Progression of COVID-19
2.4 The Incubation Period for COVID-19
2.5 Duration of the Disease
2.6 Case Fatality Rate
2.6.1 CFR for COVID-19 by Age
2.6.2 CFR for COVID-19 by Pre-Existing Health Issues
2.6.3 Case Fatality Rate for Select Countries and the World
2.7 Modes of COVID-19 Transmission
2.8 Clinical Case Management

3. GLOBAL STATISTICS ON COVID-19
3.1 The Steady Increase in Global Number of Confirmed Cases
3.1.1 Steep Increase in COVID-19 Deaths
3.1.2 Number of COVID-19 Confirmed Cases by Geography as of May 21, 2020
3.1.3 Number of COVID-19 Deaths by Geography as of May 21, 2020
3.1.4 China Returning to Normalcy
3.1.5 COVID-19 Deaths in China
3.2 Top Five Most Affected Countries
3.2.1 COVID-19 in the U.S.
3.2.1.1 COVID-19 Deaths in the U.S.
3.2.2 COVID-19 Confirmed Cases in U.K.
3.2.2.1 COVID-19 Deaths in U.K.
3.2.3 COVID-19 Confirmed Cases in Italy
3.2.3.1 COVID-19 Deaths in Italy
3.2.4 COVID-19 Confirmed Cases in France
3.2.4.1 COVID-19 Deaths in France
3.2.5 COVID-19 Confirmed Cases in Spain
3.3 COVID-19 Deaths Compared with Deaths Due to Other Diseases
3.4 The Ebb and Flow of COVID-19 Cases
3.5 Africa Spared the Worst of the Pandemic
3.6 Number of Laboratory Tests Conducted by Select Countries
3.7 Top Four Countries with Number of COVID-Tests

4. FUNDING FOR COVID-19 RESEARCH
4.1 Contributions to WHO for COVID-19 Appeal
4.1.1 Contingency Fund for Emergencies
4.2 National Institutes of Health (NIH) Funding for COVID-19 Research
4.3 Funding for COVID-19 Research from U.S. Stimulus Bill

5. PUBLISHED SCIENTIFIC PAPERS ON COVID-19
5.1 Published Papers by Category
5.2 Notable Journal Articles

6. PATENTS OF SARS AND MERS WITH POSSIBLE RELEVANCE TO COVID-19
6.1 Types of SARS and MERS Patents
6.2 Key Proteins Described in the Patents and their Roles in Viral Infection
6.3 Patents and Potential Drug Candidates Related to Key Protein Targets
6.4 Patents of Existing Drugs with Potential Applications for COVID-19
6.5 Selected Patents Related to Small Molecule Drug Candidates
6.5.1 Compounds with Potential Effects on Key Proteins of COVID-19
6.5.2 Small Molecules Identified by Structure Similarity and Therapeutic Usage
6.6 Distributions of Biologics Patents Related to SARS and MERS
6.6.1 Patents of SARS Antibodies
6.7 Distribution of Patents of Vaccines Related to SARS/MERS
6.8 Distribution of RNAi Patents related to SARS/MERS

7. CLINICAL TRIALS LANDSCAPE FOR COVID-19
7.1 COVID-19 Clinical Trials by Country/Region
7.2 Clinical Trials by Study Type
7.2.1 Types of Interventions in the Ongoing COVID-19 Clinical Trials
7.2.1.1 Proposed Pharmacological Interventions in COVID-19 Clinical Trials
7.2.1.2 ATMPs under Investigation in COVID-19 Trials
7.3 COVID-19 Clinical Trials by Stage of Development
7.3.4 COVID-19 Clinical Trials by Funding Type
7.3.4.1 Industry-Sponsored Clinical Trials against COVID-19
7.4 Upcoming Readouts from Ongoing COVID-19 Clinical Trials

8. COVID-19’S NEGATIVE/POSIVE IMPACTS ON HEALTHCARE INDUSTRY
8.1 Negative Impacts
8.1.1 Disruption of Big Clinical Trials by COVID-19 Pandemic
8.1.2 15-Fold Increase in Clinical Trial Suspensions
8.1.3 Specific Examples of Clinical Trials Threatened by COVID-19
8.1.4 Delayed Readouts due to COVID-19
8.1.5 Shortages of Patients for Phase III due to COVID-19
8.1.6 Most Hit Pivotal Trials
8.1.7 Threat to Trials of Near-Term Blockbusters
8.1.8 COVID-19’s Deleterious Effects on Elective Procedures
8.1.9 COVID-19 Infected Cardiovascular Companies
8.1.10 Delayed Acquisitions due to COVID-19
8.1.11 Stalling of Biotech Flotations by COVID-19
8.1.12 Financial Damages to the Pharmaceutical Industry due to COVID-19
8.2 Positive Impacts
8.2.1 Sizeable Opportunities for Some Collaborations
8.2.2 COVID-19 Market Movers
8.2.3 COVID-19 Events that Pushed the Share Prices up
8.2.3.1 Johnson & Johnson
8.2.3.2 Gilead Sciences
8.2.3.3 Roche
8.2.3.4 Sanofi
8.2.3.5 BioNTech
8.2.3.6 Moderna
8.2.3.7 Vir Biotechnology
8.2.3.8 Takeda
8.2.3.9 CytoDyn
8.2.4 COVID-19-Related Stock Risers

9. MEDICINES IN DEVELOPMENT FOR COVID-19
9.1 The First Medicine to Reach the Market
9.1.1 Spectrum of Drugs
9.1.2 Difficulties in Making a Drug in Time
9.1.2.1 Bargain Search
9.1.2.2 Three Stages in Development
9.1.2.3 Massive Demand
9.1.3 Generic for Remdesivir
9.1.4 Concern about Access to COVID-19 Medicine
9.2 FDA’s CTAP to Accelerate COVID-19 Drug Development
9.2.1 CTAP’s Activities in a Snapshot

10. EMERGING VACCINE TREATMENTS FOR COVID-19
10.1 Protein Sub-Unit Vaccines in Development against COVID-19
10.2 RNA-Based Vaccines
10.3 Non-Replicating Viral Vector Vaccines
10.4 DNA Vaccines in Development for COVID-19
10.5 Inactivated Virus Vaccines in Development for COVID-19
10.6 Virus-like Particle Vaccines in Development for COVID-19
10.7 The Nearest Vaccine
10.8 Additional COVID-19 Vaccine Projects
10.9 CEPI’s Call for Vaccine Fund
10.10 Clinical Trial Costs for Developing a Viral Vaccine
10.11 The Usual Pattern of Revenue Generation by Viral Vaccines
10.11.1 Historical Sales of Vaccines for Previous Pandemics
10.11.2 Historic Sales of H1N1 Influenza Vaccines
10.12 Recent Vaccine Collaborations
10.13 Companies Capable of Producing Vaccines on a Global Scale
10.14 Big Pharma in COVID-19 Vaccines

11. ANTIBODY THERAPIES IN DEVELOPMENT FOR COVID-19

12. ANTIVIRAL DRUGS IN DEVELOPMENT FOR COVID-19
12.1 Estimated Cost of COVID-19 Antiviral Therapeutic Development
12.2 A Competitor for Gilead
12.3 Remdesivir: The First to Reach the Market
12.3.1 Hints of a Hope from Remdesivir Results
12.3.2 Interim Data for Remdesivir
12.3.3 Sales Forecast for Remdesivir
12.4 Structure of Remdesivir
12.4.1 Mechanism of Action of Remdesivir
12.5 Additional COVID-19 Therapeutic Projects

13. REPURPOSED DRUG CANDIDATES AGAINST COVID-19

14. CELL-BASED THERAPIES IN DEVELOPMENT FOR COVID-19
14.1 Brief Descriptions of Stem Cell-Based Clinical Trials for COVID-19
14.1.1 NCT04313322 (Stem Cells Arabia)
14.1.2 NCT04366063 (Royan Institute)
14.1.3 NCT04252118 (Beijing 302 Hospital)
14.1.4 NCT04346368 (Guangzhou Institute of Respiratory Disease)
14.1.5 NCT04331613 (Chinese Academy of Sciences)
14.1.6 NCT04390139 (Banc de Sang i Teixits)
14.1.7 NCT04355728 (Camillo Ricordi)
14.1.8 NCT04299152 (Tianhe Stem Cell Biotechnologies, Inc)
14.1.9 NCT04269525 (ZhiYong Peng)
14.1.10 NCT04390152 (BioXcellerator)
14.1.12 NCT04362189 (Hope Biosciences)
14.1.13 NCT04371393 (Icahn School of Medicine/Mesoblast, Inc)
14.1.14 NCT04365101 (Celularity Incorporated)
14.1.15 NCT04367077 (Athersys, Inc)
14.2 MSCs: The Most SuiTable Cells to be used Against COVID-19

15. MEDICAL DEVICES IN DEVELOPMENT FOR COVID-19
15.1 The Scramble for Mechanical Ventilators
15.2 Ventilator Shortages

16. COMMERCIALLY AVAILABLE DIAGNOSTICS FOR COVID-19
16.1 PCR Tests (Viral RNA Tests)
16.2 Serology Tests (Antibody Tests)
16.3 Antigen Tests
16.3.1 Number of EUAs Granted to Viral RNA Tests and Antibody Tests
16.3.2 Specific Issues with Antibody Tests
16.3.3 Roche’s Antibody Test: Maximum Sensitivity and Specificity
16.4 The First COVID-19 Antigen Test
16.5 At-Home COVID-19 Sample Collection Kit
16.6 Top Ten COVID-19 Diagnostic Companies
16.7 The Deluge of Testing Options

17. MARKET ANALYSIS
17.1 Global COVID-19 Vaccine Market
17.2 Global Market for Antiviral Drugs against COVID-19
17.3 Global Market for Diagnostic Tests for COVID-19
17.3.1 Global Market for COVID-19 Testing Kits by Technology
17.4 COVID-19 Addressable Personal Protection Equipment (PPE) Market17.5 Estimated COVID-19 Addressable Critical Care Device Market
17.6 Global Market for “Other” COVID-19-Related Medical Supplies
17.6.1 Market Shares of Face Masks by Type of Material
17.6.2 Global Market Share for Hand Sanitizers by Type
17.7 Global COVID-19 Treatment Market

18. CELL THERAPY COMPANIES JOINING FORCES AGAINST COVID
18.1 Aspire Health Science
18.1.1 Filing of Investigational New Drug
18.1.2 ACT-20
18.2 Athersys, Inc.
18.2.1 MultiStem
18.2.2 MultiStem for COVID-19
18.2.3 MACOVIA Study
18.3 AlloVir
18.3.1 Technology
18.4 Bonus BioGroup, Ltd.
18.4.1 MesenCure
18.5 Caladrius Biosciences
18.5.1 CLBS12
18.5.2 CLBS14
18.5.3 CLBS16
18.5.4 CLBS119 for COVID-19
18.5.5 CLBS03
18.6 Capricor Therapeutics
18.6.1 CAP-1002
18.6.2 Exosomes
18.6.3 CAP-1002 for COVID-19
18.7 Celularity
18.7.1 IMPACT Platform
18.7.2 Collaboration with United Therapeutics
18.8 Celltex Therapeutics Corporation
18.8.1 FDA Approval Sought
18.9 Citius Pharmaceuticals, Inc.
18.9.1 License Agreement with Novellus, Inc.
18.10 Cynata Therapeutics
18.10.1 Cynata and COVID-19
18.11 FibroGenesis
18.11.1 PneumoBlast
18.11.2 Patent for COVID-19 Induced ARDS
18.12 GC LabCell
18.13 Global Institute of Stem Cell Therapy and Research (GIOSTAR)
18.13.1 FDA Approval for COVID-19 Trial
18.14 Healios KK
18.14.1 New Treatment for ARDS
18.15 Hope Biosciences
18.15.1 Stem Cell Banking for Newborns
18.15.2 Stem Cell Banking for Adults
18.15.3 FDA Clearance for Phase II Trial of COVID-19
18.16 Kimera Labs, Inc.
18.16.1 Products
18.16.1.1 Exosomes: A Possible Therapy for COVID-19
18.17 Lattice Biologics, Ltd.
18.17.1 Products
18.17.2 Clinical Trial
18.18. Lineage Cell Therapeutics, Inc.
18.18.1 Cell Therapy Programs
18.18.1.1 OpRegen
18.18.1.2 OPC1
18.18.1.3 VAC2
18.18.1.4 COVID-19 Vaccine Development
18.19 Mesoblast, Ltd.
18.19.1 Remestemcel-L
18.19.2 Phase II/III Trial of Remestemcel-L
18.20 NantKwest, Inc.
18.20.1 NantKwest and ImmunityBio against COVID-19
18.21 Orbsen Therapeutics
18.21.1 Orbsen’s ORBCEL for COVID-19
18.22 Organicell
18.22.1 Organicell Flow
18.22.2 Organicell Flow for COVID-19
18.23 Pluristem Therapeutics, Inc.
18.23.1 Pluristem’s Drug Development Alliance against COVID-19
18.24 Tianhe Stem Cell Biotechnologies, Inc.
18.25 The Cure Alliance
18.25.1 Cure Alliance’s Alliance with University of Miami against COVID-19
18.26 Vitro Biopharma
18.26.1 Cell Therapy for COVID-19

19. OTHER COMPANIES/INSTITUTIONS SPONSORING TRIALS FOR COVID-19
19.1 AlloVir and Baylor College of Medicine
19.2 Biostar Stem Cell Research Institute
19.3 CAR-T (Shanghai) Biotechnology, Co., Ltd
19.4 Orgenesis’ Cell-Based Vaccine
19.5 Peking University
19.6 REMSTEM’s Phase I/IIa for COVID-19
19.7 University of Miami-COVID-19 Research Programs
19.8 Wuhan Hamilton Biotechnology

APPENDIX
Appendix 1: History of Pandemics
Appendix 1.1: A Timeline of Historical Pandemics
Appendix 1.2: Importing Disease
Appendix 1.3: Tracking Infectiousness
Appendix 1.4: Urbanization and Spread of Pandemics
Appendix 2: Global Pandemic Preparedness by Country
Appendix 3: The Math behind Social Distancing
Appendix 3.1: Effectiveness of Social Distancing
Appendix 4: Recent COVID-19 News in Brief
Appendix 4.1: Multiple Clinical Trials Test NO Gas for COVID-19
Appendix 4.2: U.S. Signed a Huge COVID-19 Drug Contract with Start-Up
Appendix 4.3: Cursory Glance at First COVID-19 Vaccine Data
Appendix 4.4: CEPI Grants $384 Million to Novavax’s COVID-19 Vaccine
Appendix 4.5: Adenoviral Vector Vaccines are the Front-Runners against COVID-19
Appendix 4.6: The Most Effective Masks for COVID-19
Appendix 4.7: FDA Approval for CRISPR-Based COVID-19 Diagnostic
Appendix 4.8: The Antiviral EIDD-2801 to Aim at COVID-19
Appendix 4.9: A Loose Alliance of Competitors against COVID-19
Appendix 4.10: About 69 Repurposed Drugs Can Block the Replication of COVID-19
Appendix 4.11: Lonza to make 1 Billion Doses of Gilead’s Remdesivir
Appendix 4.12: Merck KGaA to Ramp up Viral Vaccine Manufacturing
Appendix 4.13: DuPont, FeDEx and U.S. Government Teamed Up for PPE
Appendix 4.14: Fujifilm Tests Favipiravir against COVID-19
Appendix 4.15: Resolution to Produce I Million Swabs per Week
Appendix 4.16: BioNTech is in the Race for Vaccine

LIST OF FIGURES
Figure 2.1: Diagrammatic Cross Sectional View of COVID-19
Figure 2.2: Structure of the Spike Protein and Enzymes of COVID-19
Figure 2.3: COVID-19 Virus’s RdRp with nsp12 and nsp7
Figure 2.4: Schematic Representation of a Protease Dimer bound with two Inhibitors
Figure 2.5: The 3D Structure of the Spike Protein
Figure 2.6: The Antibody CR3022 Binding with the Spike Protein
Figure 2.7: Human Protein Complex Showing the Potential Binding Sites for the Virus
Figure 2.8: The Binding of Coronavirus to Target Protein on Human Cell
Figure 2.9: The Crystal Structure of the Enzyme ACE2
Figure 2.10: The Symptoms of COVID-19
Figure 2.11: CFR for COVID-19 in China over Time and Location
Figure 2.12: CFR for COVID-19 by Age
Figure 2.13: CFR for COVID-19 by Pre-Existing Health Issues
Figure 2.14: Case Fatality Rate for Select Countries and the World
Figure 3.1: The Steady Increase in Global Number of Confirmed Cases
Figure 3.2: Steep Increase in COVID-19 Deaths
Figure 3.3: Number of COVID-19 Confirmed Cases by Geography as of May 21, 2020
Figure 3.4: Number of COVID-19 Deaths by Geography as of May 21, 2020
Figure 3.5: Number of COVID-19 Confirmed Cases in China, Jan-22 to May-21, 2020
Figure 3.6: COVID-19 Deaths in China
Figure 3.7: COVID-19 in the U.S.
Figure 3.8: COVID-19 Deaths in the U.S.
Figure 3.9: COVID-19 Confirmed Cases in U.K.
Figure 3.10: COVID-19 Deaths in U.K.
Figure 3.11: COVID-19 Confirmed Cases in Italy
Figure 3.12: COVID-19 Deaths in Italy
Figure 3.13: COVID-19 Confirmed Cases in France
Figure 3.14: COVID-19 Deaths in France
Figure 3.15: COVID-19 Confirmed Cases in Spain
Figure 3.16: Number of COVID-19 Confirmed Cases in Africa
Figure 3.17: Top Four Countries in COVID-19 Testing
Figure 4.1: WHO’s Estimated Fund to be raised in Response to COVID-19
Figure 5.1: Number of COVID-19-Related Scientific Papers
Figure 6.1: Distribution of Patents Related to SARS and MERS
Figure 6.2: Distributions of Biologics Patents Related to SARS and MERS
Figure 6.3: Distribution of Patents of Vaccines Related to SARS/MERS
Figure 7.1: Percent Share of Clinical Trials for COVID-19 by Region
Figure 7.2: Number of Clinical Trials for COVID-19 by Study Type
Figure 7.3: Percent Shares of Interventional Types in COVID-19 Clinical Trials
Figure 7.4: COVID-19 Clinical Trials by Stage of Development
Figure 7.5: COVID-19 Clinical Studies by Funding Type
Figure 8.1: Clinical Trial Terminations/Withdrawals/Suspensions
Figure 8.2: Biotech IPOs by the quarter
Figure 8.3: Market Cap Gain and Loss by Size Bracket between Q4 2019 and Q1 2020
Figure 8.4: Key COVID-19 Market Movers as of April 1, 2020
Figure 9.1: Percent Share of Emerging Treatments and Vaccines for COVID-19
Figure 10.1: Percent Share of Different Types of Vaccines in Development
Figure 10.2: Pattern of Revenue Generation by Flu Vaccine of GlaxoSmithKline
Figure 10.3: Historic Sales of H5N1 Vaccines
Figure 10.4: Historic Sales of H1N1 Influenza Vaccines
Figure 10.5: World’s Biggest Vaccine Makers and their Vaccine Sales
Figure 12.1: Sales of Roche’s Antiviral Tamiflu
Figure 12.2: Consensus Sales Forecast for Remdesivir
Figure 12.3: Structure of Remdesivir
Figure 12.4: Mechanism of Action of Remdesivir
Figure 16.1: EUAs Granted to COVID-19 Tests
Figure 16.2: EUA for Antigen Test and Home Test Kits
Figure 17.1: Estimated Global Market for COVID-19 Vaccines, 2020-2027
Figure 17.2: Global Market for COVID-19 Drugs, 2020-2027
Figure 17.3: Global Market for COVID-19 Testing Kits by Geography, 2020-2027
Figure 17.4: Global Market for COVID-19 Testing Kits by Technology, 2020-2027
Figure 17.5: COVID-19 Impacted Market for PPE Products, 2020-2027
Figure 17.6: Estimated COVID-19 Addressable Critical Care Device Market, 2020-2027
Figure 17.7: Global Market for Face Masks, 2020-2027
Figure 17.8: Market Shares of Face Masks by Type of Material
Figure 17.9: Global Market Share for Hand Sanitizers by Type
Figure 17.10: Global Market for COVID-19 Treatment, 2020-2027
Figure 18.1: Tianhe’s Stem Cell Educator Therapy
Figure App. 3.1: Social Distancing and Final Illness Attacking Rate

LIST OF TABLES
Table 3.1: Total Confirmed Cases and Deaths from COVID-19
Table 3.2: Average Death per day due to Various Diseases
Table 3.3: Countries with Confirmed New Cases Decreasing/Increasing as of May
Table 3.4: Number of COVID-19 Confirmed Cases in Africa
Table 3.5: COVID-19 Tests Performed per 1,000 people by Select Country
Table 3.6: Top Four Countries in COVID-19 Testing
Table 4.1: Contributions to WHO for COVID-19 as of May 20, 2020
Table 4.2: CFE’s Allocations in 2020
Table 4.3: NIH Funding for COVID-19 Research as of May 27, 2020
Table 4.4: COVID-19 Research Fund through CARES Act in the U.S.
Table 5.1: Number of Published Papers by Category as of May 24, 2024
Table 5.2: Notable Journal Articles
Table 6.1: Key Proteins and their Roles in Viral Infection
Table 6.2: Patents and Potential Drug Candidates Related to Key Protein Targets
Table 6.3: Existing Drugs with Potential Applications for COVID-19
Table 6.4: Selected Patents Related to Small Molecule Drug Candidates
Table 6.5: Select Small Molecule Compounds in R&D to Treat COVID-19
Table 6.6: Small Molecules Identified by Structure Similarity and Therapeutic Usage
Table 6.7: Patents on Developing Therapeutic Antibodies against SARS
Table 6.8: Distribution of RNAi Patents related to SARS/MERS
Table 7.1: Number of Clinical Trials for COVID-19 by Country/Region
Table 7.2: Number of Clinical Trials for COVID-19 by Study Type
Table 7.3: Drugs used as Pharmacological Interventions in COVID-19 Trials
Table 7.4: COVID-19 Clinical Trials by Stage of Development
Table 7.5: COVID-19 Clinical Studies by Funding Type
Table 7.6: Commercial Projects in Clinical Trials for COVID-19
Table 7.7: Upcoming Readouts from Ongoing COVID-19 Clinical Trials
Table 8.1: The Ten Most Affected Biotechs Due to COVID-19 Crisis
Table 8.2: Clinical Trial Terminations/Withdrawals/Suspensions
Table 8.3: Valuable R&D Assets under Threat of Delay Due to COVID-19
Table 8.4: Commercially Sponsored Pivotal Trials due to Readout by the end of 2020
Table 8.5: Phase III Trials facing Shortages of Patients due to COVID-19
Table 8.6: The Biggest Phase III Trials that are still searching for Patients
Table 8.7: Threat to Trials of Near-Term Blockbusters
Table 8.8: COVID-19 Infected Orthopedic Companies
Table 8.9: COVID-19-Infected Cardiovascular Firms
Table 8.10: Select Pending Acquisitions in Healthcare
Table 8.11: Select COVID-19 Deals and Collaborations
Table 8.12: Key COVID-19 Market Movers as of April 1, 2020
Table 8.13: COVID-19-Related Stock Risers
Table 9.1: Current Count on Emerging Treatments and Vaccines for COVID-19
Table 10.1: Types of Vaccines in Development
Table 10.1: Protein Sub-Unit Vaccines in Development against COVID-19
Table 10.2: RNA-Based Vaccines in Development for COVID-19
Table 10.3: Non-Replicating Viral Vector Vaccines in Development for COVID-19
Table 10.4: DNA Vaccines in Development for COVID-19
Table 10.5: Inactivated Virus Vaccines in Development for COVID-19
Table 10.6: Virus-like Particle Vaccines in Development for COVID-19
Table 10.7: Additional COVID-19 Vaccine Projects
Table 10.8: Cepi’s Call for Funding
Table 10.9: Estimated Cost of Select Pandemic Clinical Programs
Table 10.10: Most Recent Collaborations in Vaccine Sector
Table 10.11: Select COVID-19 Vaccines with Big Pharma Involvement
Table 11.1: Antibody Drugs in Development for COVID-19
Table 12.1: Antiviral Drugs in Development for COVID-19
Table 12.2: Estimated Cost of COVID-19 Clinical Program (Remdesivir)
Table 12.3: Comparison of Remdesivir’s Three Datasets
Table 12.4: Interim Data from Gilead’s Trial (NCT04292899)
Table 12.5: Additional COVID-19 Therapeutic Projects
Table 13.1: Repurposed Drugs in Development for COVID-19
Table 14.1: Cell-Based Therapies in Development for COVID-19
Table 15.1: Medical Devices in Development for COVID-19
Table 15.2: Select Makers of Modifiable Devices Eligible for EUAs
Table 15.3: Number of FDA-Approved Ventilators between 2014 and 2020
Table 16.1: Accuracy Figures for Select COVID-19 Antibody Tests
Table 16.2: Accuracy Figures for Top Eight COVID-19 Antibody Tests
Table 16.3: Top Ten COVID-19 Diagnostic Companies
Table 16.4: Commercially Available COVID-19 Diagnostic Tests
Table 17.1: Estimated Global Market for COVID-19 Vaccines, 2020-2027
Table 17.2: Global Market for COVID-19 Drugs, 2020-2027
Table 17.3: Global Market for COVID-19 Testing Kits by Geography, 2020-2027
Table 17.4: Global Market for COVID-19 Testing Kits by Technology, 2020-2027
Table 17.5: COVID-19 Impacted Market for PPE Products, 2020-2027
Table 17.6: Estimated COVID-19 Addressable Critical Care Device Market, 2020-2027
Table 17.7: Global Market for “Other” COVID-19-Related Medical Supplies, 2020-2027
Table 17.8: Global Market for COVID-19 Treatment, 2020-2027
Table App. 1.1: A Timeline of Historical Pandemics
Table App. 1.2: Ro Number of Pandemics
Table App. 2.1: Global Health Security Index Score

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AlloVir
  • AlloVir and Baylor College of Medicine
  • Aspire Health Science
  • Athersys, Inc
  • Banc de Sang i Teixits
  • Beijing 302 Hospital
  • BioNTech
  • Biostar Stem Cell Research Institute
  • BioXcellerator
  • Bonus BioGroup, Ltd.
  • Caladrius Biosciences
  • Camillo Ricordi
  • Capricor Therapeutics
  • CAR-T (Shanghai) Biotechnology, Co., Ltd
  • Celltex Therapeutics Corporation
  • Celularity Incorporated
  • Chinese Academy of Sciences
  • Citius Pharmaceuticals, Inc.
  • ClinicalTrials.gov
  • Cynata Therapeutics
  • CytoDyn
  • FibroGenesis
  • GC LabCell
  • Gilead Sciences
  • Global Institute of Stem Cell Therapy and Research (GIOSTAR)
  • Guangzhou Institute of Respiratory Disease
  • Healios KK
  • Hope Biosciences
  • Icahn School of Medicine/Mesoblast, Inc
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Kimera Labs, Inc.
  • Lattice Biologics, Ltd.
  • Lineage Cell Therapeutics, Inc.
  • Mesoblast, Ltd.
  • Moderna, Inc
  • NantKwest, Inc.
  • Orbsen Therapeutics
  • Organicell
  • Orgenesis
  • Peking University
  • Pluristem Therapeutics, Inc.
  • Regeneron
  • REMSTEM
  • Roche
  • Royan Institute
  • Sanofi
  • Stem Cells Arabia
  • Takeda
  • The Cure Alliance
  • Tianhe Stem Cell Biotechnologies, Inc
  • Toyama Chemical
  • University of Miami
  • Vir Biotechnology
  • Vitro Biopharma
  • World Health Organization (WHO)
  • Wuhan Hamilton Biotechnology
  • ZhiYong Peng
Note: Product cover images may vary from those shown
5 of 4

The content and statistics contained within the publisher's reports are compiled using a broad range of sources, as described below.

Input Sources

  • Clinical Trial Databases (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register, Chinese Clinical Trial Registry, Others)
  • Scientific Publication Databases (PubMed, Highwire Press, Google Scholar)
  • Patent Databases (United States Patent and Trade Office, World Intellectual Property Organization, Google Patent Search)
  • Grant Funding Databases (RePORT Database, CIRM, MRC, Wellcome Trust - UK, Others)
  • Product Launch Announcements (Trade Journals, Google News)
  • Industry Events (Google News, Google Alerts, Press Releases)
  • Company News (SEC Filings, Investor Publications, Historical Performance)
  • Social Analytics (Google Adwords, Google Trends, Twitter, Topsy.com, Hashtagify.me, BuzzSumo.com)
  • Interviews with Stem Cell Industry Leaders

Research & Analysis Methodologies

The publisher employs the following techniques for deriving its market research:

  • Historical Databases: As the first and only market research firm to specialize in the stem cell industry, the publisher has 13+ years of historical data on each segment of the stem cell the industry. This provides an extremely rare and robust database for establishing market size determinations, as well as making future market predictions.
  • Prolific Interviews with Industry Leaders: As the global leader in stem cell industry data, the publisher has interviewed hundreds of leaders from across the stem cell industry, including the CEO of FUJIFILM CDI, FUJIFILM Irvine Scientific, Pluristem Therapies, Celularity, and many others.
  • Industry Relationships: The research team and its President/Founder, Cade Hildreth, Chair and present at a wide range of stem cell industry events, including Phacilitate's Advanced Therapies Week, World Stem Cell Summit (WSCS), Perinatal Stem Cell Society Congress, AABB's International Cord Blood Symposium (ICBS), and other events hosted within the U.S. and worldwide.
  • Global Integrated Feedback: Because the publisher maintains the world's largest stem cell industry news site that is read by nearly a million unique readers per year and the company has large social media audiences (25.7K+ followers on Linked, 21.2K+ followers on Twitter, and 4.3K+ followers on Facebook), the publisher is able to publish content relevant to the industry and receive immediate feedback/input from a global community of readers. In short, the publisher's data is crowd-sourced from market participants worldwide, including those in diverse geographic regions.
  • Preliminary Research: In addition to the interviews described above, the publisher conducts market surveys, executes social media polls, and aggregates market data from stem cell industry announcements, press releases, and corporate filings/presentations.
  • Secondary Research: The publisher summarizes, collects and synthesizes existing market research that is relevant to the market area of interest.
  • Future Projections: Using the resources described above, the publisher is uniquely positioned to make future projections about market size, market growth by segment, market trends, technology evolution, funding activities (financing rounds, M&A, and IPOs), and importantly, market leadership (market share by company).
 

Loading
LOADING...

Adroll
adroll